Pfenex Exercises Glide Contract Extension for Solid Dose Formulation of Recombinant Protective Antigen (rPA)-Based Anthrax Vaccine

OXFORD, England, March 9, 2015 /PRNewswire/ --

Glide Technologies announced today a subcontract extension for the advancement of an alternative delivery method for Pfenex's recombinant Protective Antigen, Px563L-mrPA, utilising the Glide Technologies solid dose formulation technology.  This contract continuation is the result of the National Institute of Allergy and Infectious Diseases (NIAID) exercising its first contract option under its existing contract (HHSN272201200033C) with Pfenex.

"We are pleased with the early results and the development of this potential additional path for our anthrax vaccine program," stated Bertrand C. Liang, Chief Executive Officer of Pfenex. "We appreciate the additional funding support provided by NIAID for this program and look forward to continuing this successful collaboration."

"Following encouraging stability data with initial formulations we are pleased that NIAID continues to fund the progression of this program. We believe that a combination of Pfenex's proprietary rPA-based anthrax vaccine and Glide's novel formulations and delivery technology will address key issues with current products designed for a response to an anthrax bio-threat," stated Dr Mark Carnegie-Brown, Chief Executive Officer of Glide Technologies.

About Glide Technologies 

Glide is a development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics.  It has a growing pipeline of products based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines.  Glide's pipeline of solid dose formulations includes octreotide, parathyroid hormone and anthrax and influenza vaccines.  Glide is also developing a novel non-invasive diagnostic technology, initially focused on prostate cancer, which aims to differentiate between clinically significant and clinically insignificant disease based on a biochemical marker.

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  Glide has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT. For more information please visit http://www.glide-technologies.com.

Contacts
Dr Mark Carnegie-Brown
Chief Executive Officer
Glide Technologies
Tel: +44(0)1235-577120

Richard Bungay
Chief Financial Officer
Glide Technologies
Tel: +44(0)1235-577120

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

SOURCE Glide Technologies